New drug or biologic application sponsors should specify the purpose of any real-world evidence submitted with their filing, as well as the real-word data sources used to generate that evidence, the US Food and Drug Administration said in a draft guidance document released 8 May.
The agency’s drugs and biologics centers will use this information to track certain types of real-world evidence (RWE) submissions under an investigational new drug